Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Innovent Announces Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer
Innovent Biologics has announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) for IBI343. This is a potentially best-in-class TOPO1i anti-CLDN18.2...
Gilead's Trodelvy® Receives Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer
Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Trodelvy® (sacituzumab govitecan-hziy) in the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy....
Tolebrutinib Receives Breakthrough Therapy Designation for Non-Relapsing Secondary Progressive Multiple Sclerosis
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). ...
HUTCHMED Announces Breakthrough Therapy Designation for ORPATHYS® and TAGRISSO® Combination for the treatment of EGFR+ NSCLC
HUTCHMED has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of ORPATHYS® (savolitinib) and TAGRISSO®...
Seres Therapeutics' SER-155 Received Breakthrough Designation for Bloodstream Infections in Stem Cell Transplant Patients
Seres Therapeutics has announced that US FDA has granted Breakthrough Therapy designation to its lead investigational product, SER-155. This designation is for reducing bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) for the treatment of blood cancers....
FDA Approved Breakthrough Therapy Designation to Stoke Therapeutics' Zorevunersen for Dravet Syndrome
Stoke Therapeutics has announced that its investigational drug, zorevunersen, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). This designation is for Zorevunersen’s potential use in treating Dravet syndrome with a confirmed mutation in the SCN1A gene that is not associated with gain-of-function....
FDA Approves Breakthrough Therapy Designation to Ultragenyx for Setrusumab (UX143) in Treating Osteogenesis Imperfecta
Ultragenyx received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for setrusumab (UX143) as a treatment to reduce fracture risk in osteogenesis imperfecta (OI) Types I, III, and IV for patients aged two years and above....
Attralus Granted Breakthrough Therapy Designation for 124I-evuzamitide in Cardiac Amyloidosis
Attralus, announced that its investigational diagnostic imaging agent, 124I-evuzamitide (AT-01), has received Breakthrough Therapy Designation (BTD) from U.S. FDA for positron emission tomography (PET) imaging in patients suspected of or diagnosed with cardiac amyloidosis. ...
Halia and Biolexis Partner Announces Novel NLRP3 Target for Neuroinflammation
Halia Therapeutics has tied up with Biolexis Therapeutics, resulting in the discovery of a novel small molecule candidate capable of crossing the blood-brain barrier and targeting neuroinflammation driven by NLRP3....
FDA Approves Tonix Pharmaceutical’s Fast Track Designation to Tonmya™ as a treatment for fibromyalgia
Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. ...
